Otsuka-FDA Row Tests Potent Anti-Generic Tool
Otsuka Pharmaceutical Co. Ltd.'s unusual lawsuit against the U.S. Food and Drug Administration over a newly approved use of mega-blockbuster Abilify will test the powerful tactic of thwarting generic competition by...To view the full article, register now.
Already a subscriber? Click here to view full article